Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.39 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5168757 | 1.00 | NOD1 (0.44) | NOD1ALDH1A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL6574312 | 1.00 | NOD1 (0.44) | NOD1ALDH1A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL28088248 | 0.94 | NOD1 (0.51) | NOD1SLC1A2SLC1A1TSHRGRIK1 | |
| SCHEMBL28088246 | 0.94 | NOD1 (0.51) | NOD1SLC1A2SLC1A1TSHRGRIK1 | |
| SCHEMBL112732 | 0.93 | ALDH1A1 (0.47) | NOD1ALDH1A1HPGDTSHRATM | |
| SCHEMBL112731 | 0.93 | ALDH1A1 (0.47) | NOD1ALDH1A1HPGDTSHRATM | |
| SCHEMBL112730 | 0.93 | ALDH1A1 (0.47) | NOD1ALDH1A1HPGDTSHRATM | |
| Hydrochloric Acid SCHEMBL28847980 | 0.91 | ALDH1A1 (0.45) | NOD1ALDH1A1HPGDTSHRATM | |
| SCHEMBL6574302 | 0.90 | KIF11 (0.40) | NOD1SLC1A2SLC1A1SLC1A3KIF11 | |
| SCHEMBL6574315 | 0.90 | KIF11 (0.40) | NOD1SLC1A2SLC1A1SLC1A3KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759748-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-0999297-B1 | Method of producing water-insolubilized regenerated collagen fibers | KANEKA CORP (JP) | 2004-05-06 | — | — | EP | disclosed |
| CN-1100165-C | Improved regenerated collagen fiber and method of manufacturing the same | KANEGAFUCHI CHEMICAL IND (JP) | 2003-01-29 | — | — | CN | disclosed |
| EP-0890663-B1 | Improved regenerated collagen fiber and method of manufacturing the same | KANEKA CORP (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-6242573-B1 | SPINNING REGENERATED AND SOLUBILIZED COLLAGEN INTO FIBER, THEN TREATING WITH INSOLUBILIZING AGENT TO LOWER ITS WATER ABSORPTION RATE; MAINTAINS COLOR AND HIGH KNOT TENACITY; PERMANENT WAVES; WIGS | KANEKA CORPORATION (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6160096-A | Regenerated collagen fiber and method of manufacturing the same | KANEKA CORPORATION (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0999297-A1 | Method of producing water-insolubilized regenerated collagen fibers | KANEKA CORPORATION (JP) | 2000-05-10 | — | — | EP | disclosed |
| CN-1207422-A | Improved regenerated collagen fiber and method of manufacturing the same | KANEGAFUCHI CHEMICAL IND (JP) | 1999-02-10 | — | — | CN | disclosed |
| EP-0890663-A2 | Improved regenerated collagen fiber and method of manufacturing the same | Kaneka Corporation (JP) | 1999-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759748-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | ATP6V1B1, GLS, REN | NOD1 1187/4885ALDH1A1 2325/4885SLC1A2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.